Azilsartan medoxomil is a prodrug, it is metabolised in azilsartan during the absorption of the drug in the gastrointestinal tract. Azilsartan is in the angiotensin-receptor blocking (ARB) drug class. This drug selectively binds to AT1 receptors as an antagonist, blocking vasoconstrictor and the aldosterone secretion that angiotensin II provokes (RAAS). Angiotensin II usually binds to angiotensin II type 1 receptor (AT1 receptor) to stimulate the synthesis of aldosterone and promote renal tubular reabsorption of sodium. This molecule also inhibits secretion of renin. The antagonist (azilsartan) of those AT1 receptor provokes a decrease in blood pressure. This drug is available as a tablet.
References
Azilsartan medoxomil Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43. doi: 10.2147/VHRM.S22595. Epub 2012 Feb 28.
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.